{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T21:48:09Z","timestamp":1790200089121,"version":"4.1.0"},"reference-count":79,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["T32AI170501"],"award-info":[{"award-number":["T32AI170501"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,3,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Castleman disease represents a heterogeneous group of hematologic conditions with a broad spectrum of histopathologic features. Historically, 2 major Castleman disease subgroups have been described\u2014unicentric Castleman disease and multicentric Castleman disease, based on the extent of the disease. More recently, oligocentric Castleman disease, a subtype that falls between unicentric and multicentric, has been identified. Due to the overlapping features of each category, similarities to other conditions, and a lack of objective diagnostic biomarkers, the diagnosis of Castleman disease remains a challenge. Here, we review the diagnostic criteria of each entity and discuss the features that distinguish them from overlapping diseases.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This review highlights the clinicopathologic features of multiple cases to depict the wide spectrum of clinical and laboratory characteristics of Castleman disease. It also outlines the diagnostic workup for each subtype.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In Castleman disease, the morphologic findings are nonspecific and represent a histologic pattern rather than a pathognomonic feature that allows definitive separation from other morphologically overlapping entities; therefore, correlation with clinical history, radiologic studies, and laboratory findings is essential to arrive at the correct diagnosis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Castleman disease represents a spectrum of clinical syndromes with overlapping morphological features.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ajcp\/aqaf147","type":"journal-article","created":{"date-parts":[[2025,12,21]],"date-time":"2025-12-21T12:42:48Z","timestamp":1766320968000},"source":"Crossref","is-referenced-by-count":1,"title":["How I diagnose Castleman disease"],"prefix":"10.1093","volume":"165","author":[{"given":"Dorottya","family":"Laczko","sequence":"first","affiliation":[{"name":"Perelman School of Medicine, University of Pennsylvania , Philadelphia, PA,","place":["United States"]},{"name":"Hospital of the University of Pennsylvania Division of Hematopathology, , Philadelphia, PA,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinodh","family":"Pillai","sequence":"additional","affiliation":[{"name":"The Children\u2019s Hospital of Philadelphia Division of Hematopathology, , Philadelphia, PA,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dale","family":"Frank","sequence":"additional","affiliation":[{"name":"Hospital of the University of Pennsylvania Division of Hematopathology, , Philadelphia, PA,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua D","family":"Brandstadter","sequence":"additional","affiliation":[{"name":"Division of Hematology-Oncology, Perelman School of Medicine, University of Pennsylvania , Philadelphia, PA,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David C","family":"Fajgenbaum","sequence":"additional","affiliation":[{"name":"Perelman School of Medicine, University of Pennsylvania , Philadelphia, PA,","place":["United States"]},{"name":"Division of Translational Medicine & Human Genetics, Perelman School of Medicine, University of Pennsylvania , Philadelphia, PA,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,3,9]]},"reference":[{"key":"2026030919575432900_aqaf147-B1","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1182\/blood.2019000931","article-title":"Overview of Castleman disease","volume":"135","author":"Dispenzieri","year":"2020","journal-title":"Blood"},{"key":"2026030919575432900_aqaf147-B2","doi-asserted-by":"publisher","first-page":"60","DOI":"10.3960\/jslrt.21036","article-title":"Historical and pathological overview of Castleman disease","volume":"62","author":"Nishimura","year":"2022","journal-title":"J Clin Exp Hematop"},{"key":"2026030919575432900_aqaf147-B3","doi-asserted-by":"publisher","first-page":"1952","DOI":"10.1182\/bloodadvances.2024014391","article-title":"Characterizing the heterogeneity of Castleman disease and oligocentric subtype: findings from the ACCELERATE registry","volume":"9","author":"Pierson","year":"2025","journal-title":"Blood Adv"},{"key":"2026030919575432900_aqaf147-B4","doi-asserted-by":"publisher","first-page":"1934","DOI":"10.1002\/ajh.27081","article-title":"POEMS syndrome: update on diagnosis, risk-stratification, and management","volume":"98","author":"Dispenzieri","year":"2023","journal-title":"Am J Hematol"},{"key":"2026030919575432900_aqaf147-B5","doi-asserted-by":"publisher","first-page":"1646","DOI":"10.1182\/blood-2016-10-746933","article-title":"International, evidence-based consensus diagnostic criteria for HHV-8-negative\/idiopathic multicentric Castleman disease","volume":"129","author":"Fajgenbaum","year":"2017","journal-title":"Blood"},{"key":"2026030919575432900_aqaf147-B6","doi-asserted-by":"publisher","first-page":"10301","DOI":"10.3390\/ijms231810301","article-title":"Idiopathic plasmacytic lymphadenopathy forms an independent subtype of idiopathic multicentric Castleman disease","volume":"23","author":"Nishikori","year":"2022","journal-title":"Int J Mol Sci"},{"key":"2026030919575432900_aqaf147-B7","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.3109\/10428194.2014.953145","article-title":"Use of a claims database to characterize and estimate the incidence rate for Castleman disease","volume":"56","author":"Munshi","year":"2015","journal-title":"Leuk Lymphoma"},{"key":"2026030919575432900_aqaf147-B8","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1634\/theoncologist.2011-0075","article-title":"Castleman\u2019s disease: systematic analysis of 416 patients from the literature","volume":"16","author":"Talat","year":"2011","journal-title":"Oncologist"},{"key":"2026030919575432900_aqaf147-B9","doi-asserted-by":"publisher","first-page":"6039","DOI":"10.1182\/bloodadvances.2020003334","article-title":"International evidence-based consensus diagnostic and treatment guidelines for unicentric Castleman disease","volume":"4","author":"van Rhee","year":"2020","journal-title":"Blood Adv"},{"key":"2026030919575432900_aqaf147-B10","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1080\/13506129.2019.1641078","article-title":"Epidemiology of Castleman disease associated with AA amyloidosis: description of 2 new cases and literature review","volume":"26","author":"Fayand","year":"2019","journal-title":"Amyloid"},{"key":"2026030919575432900_aqaf147-B11","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.rmcr.2018.08.002","article-title":"Unicentric Castleman disease complicated by paraneoplastic bronchiolitis obliterans and pemphigus","volume":"25","author":"Raza","year":"2018","journal-title":"Respir Med Case Rep"},{"key":"2026030919575432900_aqaf147-B12","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1111\/bjd.14162","article-title":"Clinical and immunological findings in 104 cases of paraneoplastic pemphigus","volume":"173","author":"Ohzono","year":"2015","journal-title":"Br J Dermatol"},{"key":"2026030919575432900_aqaf147-B13","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1097\/00000478-199007000-00001","article-title":"Development of vascular neoplasia in Castleman\u2019s disease. Report of seven cases","volume":"14","author":"Gerald","year":"1990","journal-title":"Am J Surg Pathol"},{"key":"2026030919575432900_aqaf147-B14","doi-asserted-by":"publisher","first-page":"6009","DOI":"10.1038\/s41467-025-61214-1","article-title":"Spatial and single cell mapping of Castleman disease reveals key stromal cell types and cytokine pathways","volume":"16","author":"Smith","year":"2025","journal-title":"Nat Commun"},{"key":"2026030919575432900_aqaf147-B15","doi-asserted-by":"publisher","first-page":"2008","DOI":"10.3390\/diagnostics11112008","article-title":"Clinical and pathological characteristics of hyaline-vascular type unicentric Castleman disease: a 20-year retrospective analysis","volume":"11","author":"Nishimura","year":"2021","journal-title":"Diagnostics (Basel)"},{"key":"2026030919575432900_aqaf147-B16","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1053\/j.semdp.2016.05.006","article-title":"Multicentric Castleman disease: where are we now?","volume":"33","author":"Wang","year":"2016","journal-title":"Semin Diagn Pathol"},{"key":"2026030919575432900_aqaf147-B17","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1007\/BF01607150","article-title":"Morpho-immunophenotypic diversity of Castleman\u2019s disease, hyaline-vascular type: with emphasis on a stroma-rich variant and a new pathogenetic hypothesis","volume":"423","author":"Danon","year":"1993","journal-title":"Virchows Arch A Pathol Anat Histopathol"},{"key":"2026030919575432900_aqaf147-B18","doi-asserted-by":"publisher","first-page":"1008587","DOI":"10.3389\/fonc.2023.1008587","article-title":"Case report: the stroma-rich variant of Castleman\u2019s disease of hyaline-vascular type with atypical stromal cell proliferation and malignant potential: an exceptional rare case occurred in mediastinal lymph node","volume":"13","author":"Shi","year":"2023","journal-title":"Front Oncol"},{"key":"2026030919575432900_aqaf147-B19","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1038\/modpathol.2013.202","article-title":"Monoclonality and cytogenetic abnormalities in hyaline vascular Castleman disease","volume":"27","author":"Chang","year":"2014","journal-title":"Mod Pathol"},{"key":"2026030919575432900_aqaf147-B20","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1038\/s41375-018-0323-6","article-title":"Recurrent PDGFRB mutations in unicentric Castleman disease","volume":"33","author":"Li","year":"2019","journal-title":"Leukemia"},{"key":"2026030919575432900_aqaf147-B21","first-page":"346","article-title":"Castleman\u2019s disease and related disorders","volume":"5","author":"Frizzera","year":"1988","journal-title":"Semin Diagn Pathol"},{"key":"2026030919575432900_aqaf147-B22","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.hoc.2017.09.004","article-title":"Pathology of Castleman disease","volume":"32","author":"Wu","year":"2018","journal-title":"Hematol Oncol Clin North Am"},{"key":"2026030919575432900_aqaf147-B23","doi-asserted-by":"publisher","first-page":"1658","DOI":"10.1182\/blood-2016-11-748855","article-title":"Clinical and pathological characteristics of HIV- and HHV-8-negative Castleman disease","volume":"129","author":"Yu","year":"2017","journal-title":"Blood"},{"key":"2026030919575432900_aqaf147-B24","doi-asserted-by":"publisher","first-page":"4924","DOI":"10.1182\/bloodadvances.2024013548","article-title":"The clinical picture of Castleman disease: a systematic review and meta-analysis","volume":"8","author":"Hoffmann","year":"2024","journal-title":"Blood Adv"},{"key":"2026030919575432900_aqaf147-B25","doi-asserted-by":"publisher","first-page":"1057683","DOI":"10.3389\/fonc.2023.1057683","article-title":"Unicentric form of Castleman s disease, pitfalls of diagnosis and surgical treatment","volume":"13","author":"Molacek","year":"2023","journal-title":"Front Oncol"},{"key":"2026030919575432900_aqaf147-B26","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1002\/ajh.23291","article-title":"The clinical spectrum of Castleman\u2019s disease","volume":"87","author":"Dispenzieri","year":"2012","journal-title":"Am J Hematol"},{"key":"2026030919575432900_aqaf147-B27","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1093\/ajcp\/aqw218","article-title":"HHV8\/KSHV-positive lymphoproliferative disorders and the spectrum of plasmablastic and plasma cell neoplasms: 2015 SH\/EAHP workshop report-part 3","volume":"147","author":"Chadburn","year":"2017","journal-title":"Am J Clin Pathol"},{"key":"2026030919575432900_aqaf147-B28","doi-asserted-by":"publisher","first-page":"e56534","DOI":"10.7759\/cureus.56534","article-title":"Human herpesvirus 8-positive multicentric Castleman disease in an immunocompetent patient: a diagnostic challenge","volume":"16","author":"Magalh\u00e3es","year":"2024","journal-title":"Cureus"},{"key":"2026030919575432900_aqaf147-B29","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1038\/nri2076","article-title":"Immune evasion by Kaposi\u2019s sarcoma-associated herpesvirus","volume":"7","author":"Coscoy","year":"2007","journal-title":"Nat Rev Immunol"},{"key":"2026030919575432900_aqaf147-B30","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1126\/science.274.5293.1739","article-title":"Molecular mimicry of human cytokine and cytokine response pathway genes by KSHV","volume":"274","author":"Moore","year":"1996","journal-title":"Science"},{"key":"2026030919575432900_aqaf147-B31","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/B978-0-12-800098-4.00002-7","article-title":"KSHV: pathways to tumorigenesis and persistent infection","volume":"88","author":"Giffin","year":"2014","journal-title":"Adv Virus Res"},{"key":"2026030919575432900_aqaf147-B32","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1038\/nrclinonc.2010.103","article-title":"Castleman\u2019s disease\u2014a two compartment model of HHV8 infection","volume":"7","author":"Schulte","year":"2010","journal-title":"Nat Rev Clin Oncol"},{"key":"2026030919575432900_aqaf147-B33","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1038\/s41572-021-00317-7","article-title":"Castleman disease","volume":"7","author":"Carbone","year":"2021","journal-title":"Nat Rev Dis Primers"},{"key":"2026030919575432900_aqaf147-B34","doi-asserted-by":"publisher","first-page":"4189","DOI":"10.1182\/blood-2013-08-519959","article-title":"Human and viral interleukin-6 and other cytokines in Kaposi sarcoma herpesvirus-associated multicentric Castleman disease","volume":"122","author":"Polizzotto","year":"2013","journal-title":"Blood"},{"key":"2026030919575432900_aqaf147-B35","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1111\/j.1365-2559.2008.03144.x","article-title":"Immunophenotypic analysis of the Kaposi sarcoma herpesvirus (KSHV; HHV-8)-infected B cells in HIV+ multicentric Castleman disease (MCD)","volume":"53","author":"Chadburn","year":"2008","journal-title":"Histopathology"},{"key":"2026030919575432900_aqaf147-B36","doi-asserted-by":"publisher","first-page":"2130","DOI":"10.1182\/blood.v97.7.2130","article-title":"Kaposi sarcoma-associated herpesvirus infects monotypic (IgM lambda) but polyclonal naive B cells in Castleman disease and associated lymphoproliferative disorders","volume":"97","author":"Du","year":"2001","journal-title":"Blood"},{"key":"2026030919575432900_aqaf147-B37","doi-asserted-by":"publisher","first-page":"3415","DOI":"10.1182\/blood-2002-02-0487","article-title":"KSHV- and EBV-associated germinotropic lymphoproliferative disorder","volume":"100","author":"Du","year":"2002","journal-title":"Blood"},{"key":"2026030919575432900_aqaf147-B38","doi-asserted-by":"publisher","first-page":"1660","DOI":"10.1182\/bloodadvances.2020004058","article-title":"Characteristics and outcomes of KSHV-associated multicentric Castleman disease with or without other KSHV diseases","volume":"5","author":"Ramaswami","year":"2021","journal-title":"Blood Adv"},{"key":"2026030919575432900_aqaf147-B39","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1097\/PAS.0b013e318160ed97","article-title":"Lymph nodes involved by multicentric Castleman disease among HIV-positive individuals are often involved by Kaposi sarcoma","volume":"32","author":"Naresh","year":"2008","journal-title":"Am J Surg Pathol"},{"key":"2026030919575432900_aqaf147-B40","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1111\/j.1440-1827.2006.02017.x","article-title":"Distinct expression of Kaposi\u2019s sarcoma-associated herpesvirus-encoded proteins in Kaposi\u2019s sarcoma and multicentric Castleman\u2019s disease","volume":"56","author":"Abe","year":"2006","journal-title":"Pathol Int"},{"key":"2026030919575432900_aqaf147-B41","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.hoc.2017.09.007","article-title":"Treatment of Kaposi sarcoma herpesvirus-associated multicentric Castleman disease","volume":"32","author":"Lurain","year":"2018","journal-title":"Hematol Oncol Clin North Am"},{"key":"2026030919575432900_aqaf147-B42","doi-asserted-by":"publisher","first-page":"3350","DOI":"10.1200\/JCO.2007.10.6732","article-title":"Prospective study of rituximab in chemotherapy-dependent human immunodeficiency virus associated multicentric Castleman\u2019s disease: ANRS 117 CastlemaB Trial","volume":"25","author":"G\u00e9rard","year":"2007","journal-title":"J Clin Oncol"},{"key":"2026030919575432900_aqaf147-B43","doi-asserted-by":"publisher","first-page":"836","DOI":"10.7326\/0003-4819-147-12-200712180-00003","article-title":"Brief communication: rituximab in HIV-associated multicentric Castleman disease","volume":"147","author":"Bower","year":"2007","journal-title":"Ann Intern Med"},{"key":"2026030919575432900_aqaf147-B44","first-page":"543","article-title":"Plasma cell dyscrasia with polyneuropathy and endocrine disorder: clinical and laboratory features of 109 reported cases","volume":"13","author":"Takatsuki","year":"1983","journal-title":"Jpn J Clin Oncol"},{"key":"2026030919575432900_aqaf147-B45","doi-asserted-by":"publisher","first-page":"4663","DOI":"10.1182\/blood-2011-06-362392","article-title":"The utility of plasma vascular endothelial growth factor levels in the diagnosis and follow-up of patients with POEMS syndrome","volume":"118","author":"D\u2019Souza","year":"2011","journal-title":"Blood"},{"key":"2026030919575432900_aqaf147-B46","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1007\/s11899-017-0367-0","article-title":"POEMS syndrome: an enigma","volume":"12","author":"Warsame","year":"2017","journal-title":"Curr Hematol Malig Rep"},{"key":"2026030919575432900_aqaf147-B47","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1212\/WNL.0b013e318263c42b","article-title":"Markedly upregulated serum interleukin-12 as a novel biomarker in POEMS syndrome","volume":"79","author":"Kanai","year":"2012","journal-title":"Neurology"},{"key":"2026030919575432900_aqaf147-B48","doi-asserted-by":"publisher","first-page":"6438","DOI":"10.1182\/blood-2010-11-316935","article-title":"Bone marrow histopathology in POEMS syndrome: a distinctive combination of plasma cell, lymphoid, and myeloid findings in 87 patients","volume":"117","author":"Dao","year":"2011","journal-title":"Blood"},{"key":"2026030919575432900_aqaf147-B49","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1002\/ajh.23644","article-title":"POEMS syndrome: 2014 update on diagnosis, risk-stratification, and management","volume":"89","author":"Dispenzieri","year":"2014","journal-title":"Am J Hematol"},{"key":"2026030919575432900_aqaf147-B50","doi-asserted-by":"publisher","first-page":"152414","DOI":"10.1016\/j.anndiagpath.2024.152414","article-title":"Castleman disease-type histopathological patterns of lymph nodes in patients with plasma cell neoplasia and POEMS syndrome","volume":"74","author":"Rodriguez-Merino","year":"2025","journal-title":"Ann Diagn Pathol"},{"key":"2026030919575432900_aqaf147-B51","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1007\/s00415-018-9110-6","article-title":"POEMS syndrome: clinical update","volume":"266","author":"Brown","year":"2019","journal-title":"J Neurol"},{"key":"2026030919575432900_aqaf147-B52","first-page":"564","article-title":"How we manage idiopathic multicentric Castleman disease","volume":"20","author":"Brandstadter","year":"2022","journal-title":"Clin Adv Hematol Oncol"},{"key":"2026030919575432900_aqaf147-B53","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1182\/bloodadvances.2021004441","article-title":"Epidemiology and treatment patterns of idiopathic multicentric Castleman disease in the era of IL-6-directed therapy","volume":"6","author":"Mukherjee","year":"2022","journal-title":"Blood Adv"},{"key":"2026030919575432900_aqaf147-B54","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1002\/hon.2969","article-title":"Bone marrow findings of idiopathic multicentric Castleman disease: a histopathologic analysis and systematic literature review","volume":"40","author":"Belyaeva","year":"2022","journal-title":"Hematol Oncol"},{"key":"2026030919575432900_aqaf147-B55","doi-asserted-by":"publisher","first-page":"2115","DOI":"10.1182\/blood-2018-07-862334","article-title":"International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease","volume":"132","author":"van Rhee","year":"2018","journal-title":"Blood"},{"key":"2026030919575432900_aqaf147-B56","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.hoc.2017.09.003","article-title":"The role of interleukin-6 in Castleman disease","volume":"32","author":"Yoshizaki","year":"2018","journal-title":"Hematol Oncol Clin North Am"},{"key":"2026030919575432900_aqaf147-B57","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1006\/cyto.2002.2012","article-title":"Anti-interleukin 6 (IL-6) receptor antibody suppresses Castleman\u2019s disease like symptoms emerged in IL-6 transgenic mice","volume":"20","author":"Katsume","year":"2002","journal-title":"Cytokine"},{"key":"2026030919575432900_aqaf147-B58","doi-asserted-by":"publisher","first-page":"4451","DOI":"10.1172\/JCI126091","article-title":"Identifying and targeting pathogenic PI3K\/AKT\/mTOR signaling in IL-6-blockade-refractory idiopathic multicentric Castleman disease","volume":"129","author":"Fajgenbaum","year":"2019","journal-title":"J Clin Invest"},{"key":"2026030919575432900_aqaf147-B59","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1002\/ajh.25123","article-title":"Plasma proteomics identifies a \u2018chemokine storm\u2019 in idiopathic multicentric Castleman disease","volume":"93","author":"Pierson","year":"2018","journal-title":"Am J Hematol"},{"key":"2026030919575432900_aqaf147-B60","doi-asserted-by":"publisher","first-page":"2924","DOI":"10.1182\/blood-2013-12-545087","article-title":"HHV-8-negative, idiopathic multicentric Castleman disease: novel insights into biology, pathogenesis, and therapy","volume":"123","author":"Fajgenbaum","year":"2014","journal-title":"Blood"},{"key":"2026030919575432900_aqaf147-B61","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.hoc.2017.09.009","article-title":"TAFRO syndrome","volume":"32","author":"Igawa","year":"2018","journal-title":"Hematol Oncol Clin North Am"},{"key":"2026030919575432900_aqaf147-B62","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1007\/s12185-016-1979-1","article-title":"Proposed diagnostic criteria, disease severity classification and treatment strategy for TAFRO syndrome, 2015 version","volume":"103","author":"Masaki","year":"2016","journal-title":"Int J Hematol"},{"key":"2026030919575432900_aqaf147-B63","doi-asserted-by":"publisher","first-page":"15","DOI":"10.2147\/JBM.S127822","article-title":"TAFRO syndrome: current perspectives","volume":"9","author":"Sakashita","year":"2018","journal-title":"J Blood Med"},{"key":"2026030919575432900_aqaf147-B64","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1002\/ajh.26292","article-title":"Validated international definition of the thrombocytopenia, anasarca, fever, reticulin fibrosis, renal insufficiency, and organomegaly clinical subtype (TAFRO) of idiopathic multicentric Castleman disease","volume":"96","author":"Nishimura","year":"2021","journal-title":"Am J Hematol"},{"key":"2026030919575432900_aqaf147-B65","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1002\/ajh.24242","article-title":"Clinicopathologic analysis of TAFRO syndrome demonstrates a distinct subtype of HHV-8-negative multicentric Castleman disease","volume":"91","author":"Iwaki","year":"2016","journal-title":"Am J Hematol"},{"key":"2026030919575432900_aqaf147-B66","doi-asserted-by":"publisher","first-page":"3445","DOI":"10.1182\/bloodadvances.2020004016","article-title":"Discovery and validation of a novel subgroup and therapeutic target in idiopathic multicentric Castleman disease","volume":"5","author":"Pierson","year":"2021","journal-title":"Blood Adv"},{"key":"2026030919575432900_aqaf147-B67","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1111\/cei.13632","article-title":"Mediterranean fever gene variants modify clinical phenotypes of idiopathic multi-centric Castleman disease","volume":"206","author":"Endo","year":"2021","journal-title":"Clin Exp Immunol"},{"key":"2026030919575432900_aqaf147-B68","first-page":"55","article-title":"Idiopathic plasmacytic lymphadenopathy with polyclonal hyperimmunoglobulinemia: a syndrome related to giant lymph node hyperplasia of plasma cell type","author":"Mori","year":"1980","journal-title":"J Jpnese Soc Lymph Tissue Res"},{"key":"2026030919575432900_aqaf147-B69","doi-asserted-by":"publisher","first-page":"1830","DOI":"10.1111\/bjh.19334","article-title":"Idiopathic multicentric Castleman disease (iMCD)-idiopathic plasmacytic lymphadenopathy: a distinct subtype of iMCD-not otherwise specified with different clinical features and better survival","volume":"204","author":"Gao","year":"2024","journal-title":"Br J Haematol"},{"key":"2026030919575432900_aqaf147-B70","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1200\/JCO.1985.3.9.1202","article-title":"A systemic lymphoproliferative disorder with morphologic features of Castleman\u2019s disease: clinical findings and clinicopathologic correlations in 15 patients","volume":"3","author":"Frizzera","year":"1985","journal-title":"J Clin Oncol"},{"key":"2026030919575432900_aqaf147-B71","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/0305-7372(95)90034-9","article-title":"Angiofollicular lymph node hyperplasia (Castleman\u2019s disease)","volume":"21","author":"McCarty","year":"1995","journal-title":"Cancer Treat Rev"},{"key":"2026030919575432900_aqaf147-B72","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1093\/ajcp\/99.4.385","article-title":"Reactive lymphadenopathies and atypical lymphoproliferative disorders","volume":"99","author":"Krishnan","year":"1993","journal-title":"Am J Clin Pathol"},{"key":"2026030919575432900_aqaf147-B73","doi-asserted-by":"publisher","first-page":"39","DOI":"10.3960\/jslrt.50.39","article-title":"Castleman\u2019s disease of the retroperitoneum: with special reference to IgG4-related disorder","volume":"50","author":"Kojima","year":"2010","journal-title":"J Clin Exp Hematop"},{"key":"2026030919575432900_aqaf147-B74","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1038\/modpathol.2009.17","article-title":"Systemic IgG4-related lymphadenopathy: a clinical and pathologic comparison to multicentric Castleman\u2019s disease","volume":"22","author":"Sato","year":"2009","journal-title":"Mod Pathol"},{"key":"2026030919575432900_aqaf147-B75","doi-asserted-by":"publisher","first-page":"269","DOI":"10.3390\/jpm10040269","article-title":"Pulmonary manifestations of plasma cell type idiopathic multicentric Castleman disease: a clinicopathological study in comparison with IgG4-related disease","volume":"10","author":"Nishimura","year":"2020","journal-title":"J Pers Med"},{"key":"2026030919575432900_aqaf147-B76","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1111\/pin.13185","article-title":"Investigation of IgG4-positive cells in idiopathic multicentric Castleman disease and validation of the 2020 exclusion criteria for IgG4-related disease","volume":"72","author":"Nishikori","year":"2022","journal-title":"Pathol Int"},{"key":"2026030919575432900_aqaf147-B77","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1111\/pin.12932","article-title":"Clinicopathological differential diagnosis of IgG4-related disease: a historical overview and a proposal of the criteria for excluding mimickers of IgG4-related disease","volume":"70","author":"Satou","year":"2020","journal-title":"Pathol Int"},{"key":"2026030919575432900_aqaf147-B78","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1016\/j.clml.2020.05.002","article-title":"Excellent outcomes with surgery or radiotherapy in the management of Castleman disease including a case of oligocentric disease","volume":"20","author":"Beckham","year":"2020","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"2026030919575432900_aqaf147-B79","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1159\/000526640","article-title":"Recent advances in Castleman disease","volume":"45","author":"Hoffmann","year":"2022","journal-title":"Oncol Res Treat"}],"container-title":["Am J Clin Pathol"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ajcp\/article-pdf\/165\/3\/aqaf147\/67282171\/aqaf147.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajcp\/article-pdf\/165\/3\/aqaf147\/67282171\/aqaf147.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T23:57:59Z","timestamp":1773100679000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajcp\/article\/doi\/10.1093\/ajcp\/aqaf147\/8512470"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":79,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3,3]]}},"URL":"https:\/\/doi.org\/10.1093\/ajcp\/aqaf147","relation":{},"ISSN":["0002-9173","1943-7722"],"issn-type":[{"value":"0002-9173","type":"print"},{"value":"1943-7722","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,3]]},"published":{"date-parts":[[2026,3]]},"article-number":"aqaf147"}}